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ABSTRACT 
Background: drug resistant malaria is spreading inexorably to areas with drug sensitive malaria 
parasites. This study compared the in vitro sensitivities of Plasmodium falciparum fresh parasite isolates, 
to some standard antimalarial drugs, in Makurdi and Masaka located over 300 km apart, in north central 
Nigeria. 
Methods: The in vitro responses of P. falciparum isolates; 43 and 39 in Makurdi and Masaka were 
evaluated by the standard schizonts growth inhibition assay in children aged 2-14 years.  
Results: The geometric mean effective concentration-EC50, EC90 and EC99 of quinine between Makurdi 
and Masaka differed significantly (P < 0.05). A similar difference (P < 0.05), was observed with the 
artesunate antimalarial at EC90 and EC99 levels, but not at EC50. No significant difference (P > 0.05) was 
observed in the EC values of amodiaquine between the two locations. 5.13 % (2/39) of parasites at Masaka 
were in vitro resistant to amodiaquine with EC50 > 80 nM.  The rest of the isolates were sensitive to the 
three antimalarial drugs at both locations. 
Conclusion: The results demonstrated low in vitro resistance of P. falciparum to amodiaquine in the 
region. Constant monitoring and intervention is needed to curtail the spread of resistance to 
antimalarials in Nigeria. 
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INTRODUCTION  
The changing patterns in the epidemiology 
of malaria worldwide have led inexorably to 
the spread of resistant strains of malaria 
parasites, and reduced efficacy to very vital 
antimalarial drugs such as chloroquine and 
sulfadoxine/pyrimethamine (1,2). The 
emergence of drug resistant malaria among 
countries in sub-Saharan Africa where the 
impact of malaria due to P. falciparum is 
most felt has created as dire necessity for 
constant surveillance and monitoring of P. 
falciparum responses to the available 
antimalarial chemotherapies used in the 
region, using appropriate measures(3). 
Constant monitoring is necessary in order to 
create a reliable national database which 
could be relied upon, to design and 
implement appropriate control measures 
aimed at preventing the wanton spread of 
multidrug resistance malaria within and 
across national borders.  
In Nigeria, despite the importance of 
surveillance data to effective malaria 
control, the existing data on parasite 
susceptibility to several antimalarial drugs 
that are used in the country other than 
chloroquine are sparse. Only a few reports 
exist, particularly on the latter (4, 5, 6). 
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Malaria epidemiology, and indeed the 
spread of multidrug resistant parasite 
strains associated with it could vary even 
within the same border due to ecological, 
environmental, demographic, and cultural 
factors associated with a given population. 
Thus different malaria control strategies 
may be needed, such as the use of two or 
more different antimalarial drugs to combat 
malaria among areas with different levels of 
malaria parasite sensitivities to a specific 
antimalarial drug. 
 
It was the aim of this surveillance study to 
determine and compare the level of in vitro 
sensitivities of P. falciparum isolates to some 
selected standard antimalarial drugs, used 
for malaria treatment in Makurdi and 
Masaka, located over 300 km apart within 
the same region of north central Nigeria, 
and to generate baseline data for future 
monitoring of parasite responses to those 
antimalarial drugs in the region. 
 
METHODS 
Study site: the study was conducted at the 
Bishop Murray Medical Centre Makurdi. 
Samples were obtained from the Medical 
Centre as well as the Primary Health Care 
Centre Masaka, a sub urban area of the 
Federal Capital Territory (Abuja) in north 
central Nigeria. Samples collected from 
Masaka were transported on wet ice to 
Makurdi and processed within 48 hours. 
The study protocol was approved by the 
local ethics committee of the hospital. It 
lasted from the malaria transmission season 
between April to October 2006.   
 
Subjects: enrolled subjects were febrile 
symptomatic children aged 2-14 years, who 
reported to the hospital with a history of 
fever, and whose guardian gave written 
informed consent. Prior to treatment, 2.5ml 
of venous blood was collected into heparin 
treated tubes, for microscopic detection of P. 
falciparum mono infections with Giemsa 
stain, and in vitro drug susceptibility test. 
Subjects with symptoms of severe malaria 
infections, a recent history of malaria pre-
treatment with antimalarial drugs, and 
confirmed severe anaemia (PCV ≥ 21%) 
were excluded from the study. Confirmed P. 
falciparum mono infections with parasite 
density of 2,000 to 80,000 asexual forms per 
µl of blood were included in the in vitro 
test.7 
 
In vitro parasite culture and growth 
inhibition assay: the in vitro cultivation of P.  
falciparum isolates followed a modification 
of the standard culture techniques (8,9). 
Malaria positive blood samples were first 
washed three times in RPMI 1640 medium, 
to remove the leukocytes and the buffy coat 
and the infected erythrocytes re-suspended 
in the culture medium at 50% haematocrit 
and stored briefly at 4оC. The parasite 
growth inhibition assay followed the 
standard procedure for schizonts 
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inhibition.7 A blood medium mixture 
(BMM) was prepared from a 1:20 dilution of 
the re-suspended infected erythrocytes, 
made in a sterile culture medium consisting 
of 10.43g RPMI 1640 (Invitrogen), 5.96g 
HEPES, and 25mM NaHCO3 (Sigma 
Aldrich), per litre of double distilled water 
and 0.5ml of 50mg/ml gentamicin, and 
supplemented with 5% albuamax II 
(Gibco).10 200µl of the BMM per well was 
pipetted on to the wells of a sterile flat 
bottom 96 well micro culture plates, pre-
dosed with a serial 2-fold varying 
concentrations of antimalarial drugs. The 
range of the final antimalarial drug 
concentrations on the plates were, 
amodiaquine: 6.25 – 400 nM; artesunate: 0.34 
– 22 nM; and quinine: 50 – 3200 nM. The 
plates were covered, placed in a humid 
candle jar, and incubated at 37°C, for 26-30 
hours,7 at the end of the incubation period, 
thick films were made, and stained with 
2.5% Giemsa stain for 35 minutes. The mean 
number of schizonts formed in duplicate 
wells per 200 asexual parasites were 
counted and recorded. 
 
Determination of effective concentrations 
(EC) and Potency ratios (PR) of 
antimalarial drugs: the number of schizont 
counts was fed into a non linear regression 
software; HN-NonLin made available free of 
charge by H. Noedl, at 
http://malaria.farch.net specific for malaria 
in vitro drug sensitivity test. Individual dose 
response curves were generated, and their 
EC50, EC90, and EC99 values determined. 
Potency ratios of each drug were estimated 
as ECx A/ECx B where x = EC values at 50%, 
90% and 99%. Standard drug resistant 
clones were not included in the assay; 
however, drug resistant P. falciparum 
parasites were identified as isolates with 
EC50 values, greater than published 
threshold values for sensitive parasite 
isolates. The threshold of resistance were; 
amodiaquine: EC50 > 80 nM, quinine: EC50 > 
800 nM (11,12). Artesunate: values not yet 
determined (13); estimated EC values were 
therefore reported as a baseline data for 
future comparison. 
 
 DATA ANALYSIS 
Geometric mean EC values and 95 % 
confidence intervals (CI) of each 
antimalarial drug were estimated for each 
site; non paired t – test was used to compare 
EC values between locations, while potency 
ratios of drugs were compared by ANOVA. 
The level of significance was set at P ≤ 0.05. 
 
RESULTS 
The percentages of P. falciparum parasite 
isolates that were successfully tested for in 
vitro drug susceptibility test against the 
three standard antimalarial drugs at the two 
sampled locations were 82.69 % (43/52) and 
76.47 % (39/51) of the original numbers that 
were subjected to the tests at Makurdi and 
Masaka respectively. The geometric mean 
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EC values of quinine between Makurdi and 
Masaka differed significantly at EC50, EC90, 
and EC99 (P < 0.05, table 1). The EC values of 
the artesunate antimalarial drug, between 
the two sites were 
statistically different at EC90, and 
EC99, but not at EC50. Comparable 
values for amodiaquine against P. 
falciparum parasite isolates at 
Makurdi and Masaka were not 
significantly different (P > 0.05). 
 
Table 1. Geometric Mean EC50 EC90 and EC99, 95% Confidence Interval (CI) of 
              Antimalarial Drugs against Plasmodium falciparum Isolates at Makurdi 
              and Masaka. 
____________________________________________________________________________________ 
  Drug               Geometric Mean EC, (95% CI) nM                     t-test      df      P-values 
                  ____________________________________ 
                         Makurdi                             Masaka                             
_______________________________________________________________________ 
 
AMQ: EC50      21.64 nM                          24.89 nM                     0.68        80       > 0.05 
                      (16.22 – 27.06)                (20.78 – 29.00) 
 
          EC90      61.86 nM                           76.54 nM                     1.89         80      > 0.05 
                     (51.46 – 72.26)                (62.43 – 90.65) 
 
         EC99      91.51 nM                            115.32 nM                   1.89         80      > 0.05 
                    (74.14 – 108.88)              (94.53 – 136.11) 
            
ART: EC50        1.06 nM                            1.05nM                        0.39        80      > 0.05 
                       (1.02 – 1.10)                     (1.05 - 1.08) 
 
          EC90        2.33 nM                             2.47 nM                      2.14         80      < 0.05 
                       (2.24 – 2.41)                     (2.38 – 2.56) 
 
         EC99         2.97 nM                            3.25 nM                       2.37         80      < 0.05 
                      (2.81 – 3.12)                     (3.06 – 3.44)            
   
QNN: EC50       232.63 nM                         286.64 nM                   5.07        80       < 0.05 
                    (219.33 – 245.93)              (270.08 – 303.20) 
 
          EC90      650.82 nM                           791.80 nM                    5.22       80       < 0.05 
                   (614.96 – 686.68)               (751.89 – 831.73) 
 
         EC99     953.63 nM                         1125.79 nM                      4.82       80      < 0.05 
                   (911.58 – 1005.68)          (1083.78 – 1167.80)            
________________________________________________________________________    
   AMQ = amodiaquine, ART = artesunate, QNN = quinine. 
 
The potency ratio of the individual 
antimalarial drugs which measured the 
different in vitro activities of amodiaquine, 
artesunate, and quinine against P. falciparum 
isolates at the two locations shows that there 
was no significant difference in the 
sensitivities of each antimalarial drug 
between Masaka and Makurdi, ANOVA (F2, 
8, df ) = 3.39 P > 0.05, table 2. 





Table 2.  Potency Ratios of the Antimalarial Drugs at Masaka and Makurdi 
________________________________________________________________ 
ECx                                                     Potency ratios of drugs 
________________________________________________ 
Amodiaquine                  Artesunate                     Quinine 
________________________________________________________________ 
50%                              1.15                               0.99                                1.23 
 
90%                              1.24                               1.06                                1.22 
 
99%                              1.30                               1.22                                1.18 
_________________________________________________________________ 
ANOVA (F2, 8, df) = 3.39, P > 0.05 
       
All the parasite isolates (100%) were in vitro 
sensitive to quinine and artesunate, at 
Makurdi and Masaka as determined by their 
individual EC responses to the drugs. In 
contrast, 5.13 % (2/39) of P. falciparum 
isolates at Masaka had values of EC50 > 80 
nM and were classified as in vitro resistant 
to amodiaquine. No isolate at Makurdi 
exhibited a similar disposition towards the 
amodiaquine antimalarial drug, table 3.   
 
 Table 3. Percentage (%) of in vitro Sensitive and Resistant Isolates of P. falciparum  
_______________________________________________________________________  
 Antimalarial Drug    location      n          in vitro sensitive (%)      in vitro resistant (%)                                        
_______________________________________________________________________ 
 
   Amodiaquine         Makurdi     43          43 (100.00%)                         -  
                                    Masaka       39          37 (94.87 %)                    2 (5.13 %) 
    
  Artesunate               Makurdi     43          43 (100.00%)                         -  
                                    Masaka       39          39 (100.00%)                         - 
    
  Quinine                   Makurdi      43          43 (100.00%)                         -  
                                    Masaka       39          39 (100.00%)                         -  
_______________________________________________________________________          
 
DISCUSSION 
The findings from the present data indicate 
that, wide differences exist in the effective 
concentration values of P. falciparum parasite 
isolates to quinine in Makurdi and Masaka.  
This was in spite of the fact that all the 
parasite isolates obtained from these 
locations were in vitro sensitive to quinine; 
isolates at Masaka had consistently higher 
geometric mean EC50, EC90, and EC99 values 
compared to those at Makurdi. This 
demonstrates that the continued use of 
quinine in these areas, and possibly, future 
development of parasite resistance to the 
drug may evolve at different intervals 
between these sites. Quinine has remained 
very useful for the treatment of chloroquine 
resistant falciparum malaria in Nigeria;5 and 
most isolates are highly in vitro sensitive to 
the drug in the country compared to other 
regions in the world (13, 14). The present 
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EC50 values of quinine in north central 
Nigeria are very close to 50% inhibitory 
concentration (IC50) = 0.25µM previously 
reported in western Nigeria nearly two 
decades ago (15), suggesting that the 
sensitivity of quinine in the country has 
remained very stable over the years, at least 
between the west and north central parts of 
Nigeria. 
The differences observed in the artesunate 
antimalarial drug at EC90, and EC99 levels, at 
the two sites may reflect inherent differences 
prevalent in the nature of P. falciparum 
parasites in Makurdi and Masaka. However 
the geometric mean EC50 values of the drug 
against parasite isolates at each site were 
low, not significantly different, and 
comparably similar to values generally 
reported for parasite isolates that were 
susceptible to the drug in other parts of the 
world.13,14 The global importance of the 
artemisinin derivatives and by extension the 
artesunate antimalarial drug in the current 
scheme of malaria treatment is predicated 
on the ability of the drugs to rapidly kill and 
eliminate the metabolically actively 
destructive stages of the human malaria 
parasites (16), and save lives. At the moment 
there is little evidence of parasite resistance 
to these drugs as has recently been found 
with other key antimalarial drugs (12,17). 
Yet, the danger still looms large as P. 
falciparum has often in the past found a way 
round to acquire resistance against other 
antimalarial drugs, the artemisinin 
derivatives may not be an exception in the 
future.  
 
Thus to delay parasite resistance and sustain 
the prolong use of these useful drugs, their 
combination with other antimalarial drugs 
have often been advocated (18). In areas 
with high sensitivity to artesunate, 
amodiaquine, and quinine as found in the 
present survey, a combination of 
artesunate/quinine for the treatment of 
severe malaria, and 
artesunate/amodiaquine for the treatment 
of acute malaria could prove very useful. 
Such combinations have been reported to 
produce high cure rates in the treatment of 
uncomplicated malaria elsewhere (19, 20), 
and reduced the high expenditure 
associated with the treatment of malaria, 
with ineffective antimalarials (21). 
 
Despite the lack of significance difference in 
the EC values of amodiaquine in Makurdi 
and Masaka at all the levels of the effective 
concentrations analysed, 5.13 % of isolates at 
Masaka were in vitro resistance to the drug, 
unlike their counterpart at Makurdi. 
Compare to a recent study in western 
Nigeria, in vitro EC values of amodiaquine 
against P. falciparum parasites were EC50 = 
0.06 µM, EC90 = 0.26µM, and EC99 = 0.59µM 
and were higher than the present values in 
north central Nigeria (22).  Moreover, 39% of 
a mere 36 parasite isolates observed in that 
study were in vitro resistant to amodiaquine, 
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which highlights wide spread in vitro 
resistance of P. falciparum isolates to 
amodiaquine in western Nigeria, and a 
noticeable gap in the in vitro susceptibility 
profiles of P. falciparum isolates to 
amodiaquine between the west and north 
central Nigeria. Thus isolates in north 
central Nigeria appear to be more in vitro 
sensitive to amodiaquine than their 
counterparts in the western part of the 
country. The present and the previous data 
also suggest that resistance to amodiaquine 
has emerged in the country, and may be 
spreading at an undetermined level. 
Increased parasite resistance to the drug in 
vivo would progressively limit the relevance 
of amodiaquine, as a viable option for 
combination therapy with artesunate in the 
treatment of uncomplicated malaria in 
Nigeria The usefulness of the 
artesunate/amodiaquine combination in 
producing high cure rates in clinical malaria 
has been demonstrated in Nigeria and other 
countries (23,24,25).     Generally, in vitro 
studies provide a clue which may be 
detectable in the clinical treatment outcome 
of parasite responses to antimalarial drugs 
in vivo. Although the potency ratios of the 
three drugs used in the current survey did 
not suggest any significant in vitro 
differences among the activities of these 
antimalarial drugs, relying solely on in vitro 
assessment to define possible activity 
similarities or otherwise of antimalarial 
drugs may not be sufficient. This is because 
in vitro studies do not take cognizance of 
acquired immunity against malaria 
parasites, which is promoted by certain 
antimalarial interventions (26). Further 
studies combining in vitro and in vivo as well 
as molecular characterization may be 
necessary to determine the actual activities 
of these antimalarial drugs in the north 
central region of Nigeria. 
 
 In conclusion, the present study has 
provided evidence of in vitro resistance of P. 
falciparum to amodiaquine in north central 
Nigeria. It might be necessary to constantly 
monitor and initiate critical control 
measures to limit the spread of resistance to 
amodiaquine and other antimalarial drugs 
in the country, which might develop as a 
result of cross resistance between drugs.    
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